


# Heads Up, Employers! Mental Health Parity is on the Front Burner

## August 10, 2021 | 12:00 - 1:00PM

# Webinar Procedures



--- ?





### **Speakers**



Kevin J. Malone Partner – Health Care & Life Sciences Practice Epstein Becker Green



**Elena Lynett** VP & Senior Consultant – National Health Compliance Practice Segal



### Mental Health Parity and Addiction Equity Act (MHPAEA)

- Requires that beneficiaries have access to benefits that are designed and delivered in a manner that doesn't discriminate against individuals with mental health conditions or substance use disorders.
- Is fundamentally a consumer-protection anti-discrimination statute
  - More similarities to the Civil Rights Act and ADA than to most forms of managed care and insurance regulations.
- Regulations and sub-regulatory guidance effectuate this antidiscrimination requirement through a complex series of tests.

Oversight and enforcement have steadily increased over the years and are now requiring comprehensive, organizational culture changes

### **Key Terms and Specific Requirements**

#### Financial requirements ("FRs") and quantitative treatment limitations (QTLs)

 MHSU benefits must be no more restrictive than the <u>predominant</u> type of financial requirements applied to <u>substantially all</u> medical/surgical ("M/S") benefits

#### Aggregate lifetime dollar limits and annual dollar limits (AL/ADLs)

- May not be applied to MHSU benefits unless they apply to at least one-third of M/S benefits, AND
- Limits for MHSU benefits accumulate jointly with, or are no more restrictive than, the limits for M/S benefits

#### Non-Quantitative Treatment Limits (NQTLs)

 Processes, strategies, evidentiary standards or other factors used to apply MHSU and M/S NQTLs must be comparable and no more stringent

### **Strengthening Parity in MHSU Benefits**

- Signed into law on December 27, 2020
- Requires group health plans to perform and document comparative analyses of the design and application of nonquantitative treatment limitations (NQTLs)
- Plans must be prepared to make these comparative analyses available to the DOL and/or HHS upon request beginning 45 days after the date of enactment (February 10, 2021)

# The new amendments also include requirements related to:

- Updated compliance program guidance
- An approach to corrective action
- Annual reporting by the Departments regarding noncompliance
- Guidance regarding participant and beneficiary complaints
- Promotion of Federal and State information sharing

### **Plan Sponsor Compliance Efforts**

Plans (plan sponsors) will need to work with benefit administrators to gather information so that the NQTL comparative analyses can be performed and documented

- DOL, HHS, and Treasury issued initial guidance regarding the new requirements on April 2, 2021 under FAQ Set 45
- Additional guidance is expected. Once issued, plans may need to work to comply with any requirements clarified by the Departments

### **Failure to Comply**

Consequences of failure to satisfy the comparative analysis requirements include:

- The plan or issuer must submit additional comparative analyses that demonstrate compliance not later than 45 days after the initial determination of noncompliance.
- Following the 45-day corrective action period, if the Departments make a final determination that the plan or issuer is still not in compliance
- The plan will then have seven days to notify covered individuals that the plan is not in compliance.

### Non-Quantitative Treatment Limits (NQTLs)

#### NQTLs include any policies or processes that serve to limit the scope or duration of benefits

- The federal rules provide a non-exhaustive list of examples
- Broad enough that almost any policy or procedure that limits access to MHSU benefits differently than M/S benefits can potentially be subject to the NQTL analysis

# Plans may not impose NQTLs on MH/SUD benefits unless any *processes, strategies, evidentiary standards, or other factors* used in applying the NQTL are

- Comparable to, and are applied no more stringently than, the processes, strategies, evidentiary standards, or other factors used in applying the limitation to medical/surgical benefits
- In the same classification

### **Analytic Framework for NQTLs**

A variety of different "tests" or analytic frameworks have been developed for NQTLs, but none are defined in regulation. However, the types of questions that regulators tend to ask include:

- Is a *reasonable rationale* provided for applying the NQTL to M/S and MH/SUD benefits, and is it applied consistently to all relevant benefits?
- Are differences in the application of the NQTL to MH/SUD benefits as compared to M/S benefits arbitrary, or *supported by evidence*?
- Are differences in the application of the NQTL to MH/SUD benefits *consistent with practice guidelines*?
- Is it *harder to "pass"* the NQTL for MH/SUD benefits than it is for M/S benefits?
- Are the consequences more severe for failing to meet the NQTL requirements as they apply to MH/SUD benefits?
- Is there a *disparate impact* on MH/SUD benefits as compared to M/S benefits?

### **Coverage Policy and Medical Management NQTLs**

#### **Examples of common product/benefits NQTLs include:**

- Medical necessity definitions
- Utilization management processes, such as prior authorization and concurrent review, step therapy, "soft limits" (numerical limits that can be exceeded for medical necessity)
- Restrictions based on facility location or type
- Limits based on clinical status of the patient (e.g., failure to complete a course of treatment, court-ordered treatment, admission standards based on danger to self or others)

#### **Common coverage policy NQTL concerns include:**

- Application of prior authorization to all benefits in a classification for MH/SUD but not for M/S
- Quantity limits on services that are not grounded in medical evidence
- Exclusions for wilderness therapy or other residential treatment settings

### **Provider Network NQTLs**

#### **Examples of common network NQTLs include:**

- Provider network development strategies
- Network admission standards
- Reimbursement rate-setting strategies and methodologies

#### **Common network-related concerns include:**

- Using Medicare rates as an anchor for M/S, but not for MH/SUD (or systematically applying a lower percentage for MH/SUD)
- Restrictions on scope of practice for nonphysician MH/SUD providers but not for non-physician M/S providers
- Quantitative metrics for network development for M/S but not for MH/SUD

### **Pharmacy NQTLs**

#### **Common pharmacy NQTLs include:**

- Formulary design and tiering
- Prior authorization, step therapy, and other utilization management
- Restrictions or exclusions based on formulation or mode of administration
- Exclusions of coverage for MH/SUD drugs or drug classes
- Restrictions on off-label prescribing
- Dosage limits

#### **Common violations:**

- Requiring a greater number of steps or "failures" for MH/SUD drugs vs. M/S
- Disparities in timeline or criteria (e.g. age or safety) for prior authorization
- Considerations applied non-uniformly for drug tiering
- Dosage limits below FDA approved levels
- Application of prior authorization in practice (though not stated in policy)

### **Key Themes in Compliance Risk**

#### **Missing foundational elements**

• Documentation of definitions, classifications, FR/QTLs, etc.

#### Lack of analysis and documentation regarding key NQTLs

- Limits or requirements related to the clinical status of the patient
- Provider network and reimbursement strategies
- Pharmacy benefit management
- Exclusions or limits related to specific treatments, conditions, or provider or facility types

### "Per se" violations

### Lack of parity compliance governance and oversight

• Process = Compliance





### **Upcoming NEBGH virtual events:**

- Aug. 16 Monday COVID-19 Update with Dr. Mark
- Nov. 18 Annual Membership Meeting